Literature DB >> 11703973

Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus.

F Abbasi1, T Asagmi, J P Cooke, C Lamendola, T McLaughlin, G M Reaven, M Stuehlinger, P S Tsao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11703973     DOI： 10.1016/s0002-9149(01)02063-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  75 in total

1.  Modulatory role of the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine (ADMA), in morphine tolerance and dependence in mice.

Authors:  Ozgur Gunduz; Cetin Hakan Karadag; Ahmet Ulugol
Journal:  J Neural Transm (Vienna)       Date:  2010-07-27       Impact factor: 3.575

2.  Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease.

Authors:  Takhar Kasumov; John M Edmison; Srinivasan Dasarathy; Carole Bennett; Rocio Lopez; Satish C Kalhan
Journal:  Metabolism       Date:  2010-09-23       Impact factor: 8.694

3.  Endotheliopathy of Obesity.

Authors:  John P Cooke
Journal:  Circulation       Date:  2020-07-27       Impact factor: 29.690

4.  Simultaneous bioanalysis of L-arginine, L-citrulline, and dimethylarginines by LC-MS/MS.

Authors:  Soyoung Shin; Sun-Mi Fung; Srinidi Mohan; Ho-Leung Fung
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-01-14       Impact factor: 3.205

Review 5.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover.

Authors:  E B Marliss; S Chevalier; R Gougeon; J A Morais; M Lamarche; O A J Adegoke; G Wu
Journal:  Diabetologia       Date:  2005-12-21       Impact factor: 10.122

7.  Temporal effects of low-dose ACE inhibition on endothelial function in Type 1 diabetic patients.

Authors:  D Yazici; D Gogas Yavuz; S Unsalan; A Toprak; M Yüksel; O Deyneli; H Aydin; H Tezcan; S Rollas; S Akalin
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

8.  Unchanged asymmetric dimethylarginine levels in non-diabetic, premenopausal obese women who have common risk factors for cardiovascular disease.

Authors:  P Cetinalp-Demircan; A Can; Selda Bekpinar; Y Unlucerci; Y Orhan
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

9.  Sequence variation in DDAH1 and DDAH2 genes is strongly and additively associated with serum ADMA concentrations in individuals with type 2 diabetes.

Authors:  Sotoodeh Abhary; Kathryn P Burdon; Abraham Kuot; Shahrbanou Javadiyan; Malcolm J Whiting; Nicholas Kasmeridis; Nikolai Petrovsky; Jamie E Craig
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

10.  The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease.

Authors:  Latika Sibal; Sharad C Agarwal; Philip D Home; Rainer H Boger
Journal:  Curr Cardiol Rev       Date:  2010-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.